Paul Matteis' Stock Ratings

Stifel Analyst

Paul Matteis is an analyst at Stifel. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 11/21/2024

Overall Average Return

-9.73%

Smart Score

42.5%

Overall Average Return Percentile

20th

Number of Ratings

131
Data brought to you by Benzinga APIs

Recent Analyst Stock Rating News

The Analyst Landscape: 29 Takes On Biomarin Pharmaceutical
Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts
In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
Analyst Expectations For Biomarin Pharmaceutical's Future
GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved